$TSOI
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Stock $tsoi

$tsoi Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000149315224014975 Filed on April 17, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue	$20.01K	$23.83K	$98.99K
YoY Change	-23.96%	177.74%	-52.12%
Cost Of Revenue	$6.727K	$10.55K	$36.77K
YoY Change	-37.12%	-77.07%	-53.71%
Gross Profit	$13.28K	$13.28K	$62.22K
YoY Change	-14.93%	-135.49%	-51.13%
Gross Profit Margin	66.37%	55.73%	62.85%
Selling, General & Admin	$399.8K	$419.6K	$1.488M
YoY Change	14.35%	-8.23%	-15.75%
% of Gross Profit	3010.62%	3159.26%	2391.59%
Research & Development	$17.57K	$150.5K	$560.7K
YoY Change	-91.57%	-42.99%	-61.1%
% of Gross Profit	132.32%	1133.36%	901.08%
Depreciation & Amortization	$76.92K	$81.78K	$311.8K
YoY Change	0.0%	63.69%	2748.35%
% of Gross Profit	579.3%	615.81%	501.09%
Operating Expenses	$417.3K	$570.1K	$2.049M
YoY Change	-25.23%	-20.96%	-36.12%
Operating Profit	-$404.0K	-$556.8K	-$1.986M
YoY Change	-25.52%	-26.61%	-35.5%
Interest Expense	-$59.52K	-$5.080K	-$404.1K
YoY Change	-148.68%	-92.78%	-162.55%
% of Operating Profit
Other Income/Expense, Net	-$59.52K		$0.00
YoY Change	198.34%		-100.0%
Pretax Income	-$463.6K	-$479.3K	-$2.222M
YoY Change	-17.58%	-49.0%	-39.56%
Income Tax	$800.00	$1.450K	$2.250K
% Of Pretax Income
Net Earnings	-$390.0K	-$427.5K	-$2.170M
YoY Change	-30.65%	-54.51%	-41.0%
Net Earnings / Revenue	-1949.74%	-1793.92%	-2191.95%
Basic Earnings Per Share	$0.00		$0.00
Diluted Earnings Per Share	$0.00	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	4.230B shares	3.736B shares	3.169B shares
Diluted Shares Outstanding	4.512B shares		3.169B shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.320K	$27.82K	$27.82K
YoY Change	-93.24%	54.21%	54.21%
Cash & Equivalents	$8.318K	$27.82K	$27.82K
Short-Term Investments
Other Short-Term Assets	$2.554M	$16.32K	$16.32K
YoY Change	4923.95%	-92.69%	-92.69%
Inventory	$17.81K	$22.57K	$22.57K
Prepaid Expenses	$15.08K	$11.04K
Receivables	$17.29K	$19.20K	$19.20K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$736.3K	$85.91K	$85.91K
YoY Change	230.34%	-72.22%	-72.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$368.9K	$499.9K	$499.9K
YoY Change	37.84%	83.06%	77.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.558M	$4.120K	$4.120K
YoY Change	-10.52%	-99.86%	-64.67%
Total Long-Term Assets	$3.039M	$3.206M	$3.206M
YoY Change	-6.91%	-2.74%	-2.74%
TOTAL ASSETS
Total Short-Term Assets	$736.3K	$85.91K	$85.91K
Total Long-Term Assets	$3.039M	$3.206M	$3.206M
Total Assets	$3.775M	$3.292M	$3.292M
YoY Change	8.25%	-8.7%	-8.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$376.9K	$404.9K	$404.9K
YoY Change	3.95%	0.72%	-1.06%
Accrued Expenses	$553.7K	$556.6K	$556.6K
YoY Change	-2.84%	4.67%	3.01%
Deferred Revenue
YoY Change
Short-Term Debt	$841.8K	$752.4K	$752.4K
YoY Change	13.23%	-28.61%	-28.61%
Long-Term Debt Due	$4.640K	$4.640K	$4.640K
YoY Change	0.0%	0.0%	0.0%
Total Short-Term Liabilities	$1.850M	$1.900M	$1.900M
YoY Change	-1.31%	-14.05%	-14.06%
LONG-TERM LIABILITIES
Long-Term Debt	$3.220K	$5.510K	$5.510K
YoY Change	-60.15%	-47.57%	-47.57%
Other Long-Term Liabilities	$85.93K	$105.0K	$105.0K
YoY Change	-24.32%
Total Long-Term Liabilities	$89.15K	$110.5K	$110.5K
YoY Change	-26.7%	951.76%	951.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.850M	$1.900M	$1.900M
Total Long-Term Liabilities	$89.15K	$110.5K	$110.5K
Total Liabilities	$1.939M	$2.167M	$2.167M
YoY Change	-2.85%	-2.43%	-2.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$21.30M	-$20.33M
YoY Change	13.23%	15.02%
Common Stock	$4.659M	$3.803M
YoY Change	48.66%	45.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.314M	$1.125M	$1.125M
YoY Change
Total Liabilities & Shareholders Equity	$3.775M	$3.292M	$3.292M
YoY Change	8.25%	-8.7%	-8.7%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$390.0K	-$427.5K	-$2.170M
YoY Change	-30.65%	-54.51%	-41.0%
Depreciation, Depletion And Amortization	$76.92K	$81.78K	$311.8K
YoY Change	0.0%	63.69%	2748.35%
Cash From Operating Activities	-$143.4K	-$205.3K	-$1.055M
YoY Change	-57.46%	-43.77%	3.63%
INVESTING ACTIVITIES
Capital Expenditures		-$3.840K	$16.16K
YoY Change		-98.08%
Acquisitions
YoY Change
Other Investing Activities		-$7.840K	-$7.840K
YoY Change
Cash From Investing Activities		-$4.000K	-$24.00K
YoY Change		-102.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$790.4K
YoY Change			77.62%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	98.26K	147.7K	1.078M
YoY Change	-77.33%	66.19%	14.27%
NET CHANGE
Cash From Operating Activities	-143.4K	-205.3K	-1.055M
Cash From Investing Activities		-4.000K	-24.00K
Cash From Financing Activities	98.26K	147.7K	1.078M
Net Change In Cash	-45.15K	-61.61K	-1.610K
YoY Change	-148.26%	-19.15%	-97.86%
FREE CASH FLOW
Cash From Operating Activities	-$143.4K	-$205.3K	-$1.055M
Capital Expenditures		-$3.840K	$16.16K
Free Cash Flow		-$201.5K	-$1.071M
YoY Change		22.05%	5.22%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Restricted Cash RestrictedCash		usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	TSOI	Shares To Be Issued SharesToBeIssued		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023	us-gaap	Other Expenses OtherExpenses		usd
CY2022	TSOI	Stock Issued During Period Value New Issues Preferred Stock StockIssuedDuringPeriodValueNewIssuesPreferredStock		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2022	TSOI	Payments For Proceeds From Notes Receivable PaymentsForProceedsFromNotesReceivable		usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2023	TSOI	Common Stock Issued For Prepaid Fees Value CommonStockIssuedForPrepaidFeesValue		usd
CY2023	TSOI	Common Stock Issued For License Value CommonStockIssuedForLicenseValue		usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability		usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash		usd
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent		usd
CY2023	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems		usd
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Security12g Title Security12gTitle	Common Stock, $0.001 par value per share
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	true
CY2023	dei	Document Fin Stmt Restatement Recovery Analysis Flag DocumentFinStmtRestatementRecoveryAnalysisFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	6581483	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4230116869	shares
CY2023	dei	Auditor Firm AuditorFirmId	5525
CY2023	dei	Auditor Name AuditorName	Fruci & Associates II, PLLC
CY2023	dei	Auditor Location AuditorLocation	Spokane, Washington
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27823	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18434	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	11003	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19196	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	25398	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	22574	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	42428	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16320	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	212352	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	85913	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	309615	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	374355	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	273078	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	125557	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8612	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2706187	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3014620	usd
CY2023Q4	us-gaap	Assets Assets	3292012	usd
CY2022Q4	us-gaap	Assets Assets	3605925	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	536118	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	531783	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	20525	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8612	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	112384	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	175063	usd
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	49616	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	65187	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	181070	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	202144	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1899586	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2210237	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	5512	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	10507	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	105032	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2010130	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2220744	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3802666978	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3802666978	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2617390830	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2617390830	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3802668	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2617392	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17670092	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	16655643	usd
CY2022Q4	TSOI	Shares To Be Issued SharesToBeIssued	126324	usd
CY2023Q4	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	21000	usd
CY2022Q4	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	21000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-20326465	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-18156651	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1125295	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1221708	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	156587	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	163473	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1281882	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1385181	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3292012	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3605925	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	98994	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	206767	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	36768	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	79440	usd
CY2023	us-gaap	Gross Profit GrossProfit	62226	usd
CY2022	us-gaap	Gross Profit GrossProfit	127327	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	474960	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	497151	usd
CY2023	us-gaap	Labor And Related Expense LaborAndRelatedExpense	433324	usd
CY2022	us-gaap	Labor And Related Expense LaborAndRelatedExpense	444865	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	148570	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	612658	usd
CY2023	us-gaap	Legal Fees LegalFees	431197	usd
CY2022	us-gaap	Legal Fees LegalFees	399902	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	560654	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1452128	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	2048705	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	3406704	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-1986479	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-3279377	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	36985	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-131475	usd
CY2023	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-17836	usd
CY2022	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	291123	usd
CY2023	us-gaap	Interest Expense InterestExpense	423265	usd
CY2022	us-gaap	Interest Expense InterestExpense	646089	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	168145	usd
CY2022	us-gaap	Other Expenses OtherExpenses	110642	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-235971	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-597083	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2222450	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3876460	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2250	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1600	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-2224700	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-3878060	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-54886	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-64079	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2169814	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3813981	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3168900801	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3168900801	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2528062958	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2528062958	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-604340	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	691520	usd
CY2022	TSOI	Stock Issued During Period Value For Prepaid Fees StockIssuedDuringPeriodValueForPrepaidFees	242320	usd
CY2022	TSOI	Stock Issued During Period Values For Salaries StockIssuedDuringPeriodValuesForSalaries	67399	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	445000	usd
CY2022	TSOI	Stock Issued During Period Value For License StockIssuedDuringPeriodValueForLicense	3107570	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1313772	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-3878060	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1385181	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1385181	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	176911	usd
CY2023	TSOI	Stock Issued During Period Values For Salaries StockIssuedDuringPeriodValuesForSalaries	110000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	790432	usd
CY2023	TSOI	Adjustments To Additional Paid In Capital Subsidiary For Services AdjustmentsToAdditionalPaidInCapitalSubsidiaryForServices	101841	usd
CY2023	TSOI	Stock Issued During Period Common Stock Issued For Land Development StockIssuedDuringPeriodCommonStockIssuedForLandDevelopment	96000	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	846217	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-2224700	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1281882	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1281882	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-2224700	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-3878060	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	101841	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	380820	usd
CY2023	TSOI	Share Based Compensation To Related Parties ShareBasedCompensationToRelatedParties	176911	usd
CY2022	TSOI	Share Based Compensation To Related Parties ShareBasedCompensationToRelatedParties	310700	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	36985	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-131475	usd
CY2023	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-17836	usd
CY2022	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	291123	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	168145	usd
CY2023	TSOI	Amortization Of Prepaid Stock Based Compensation AmortizationOfPrepaidStockBasedCompensation	116793	usd
CY2022	TSOI	Amortization Of Prepaid Stock Based Compensation AmortizationOfPrepaidStockBasedCompensation	951748	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	384744	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	593463	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300897	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	233685	usd
CY2023	us-gaap	Depreciation Depreciation	10881	usd
CY2022	us-gaap	Depreciation Depreciation	10946	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6202	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8785	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-19854	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2611	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-94618	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-354989	usd
CY2023	TSOI	Increase Decrease In Right Of Use Asset IncreaseDecreaseInRightOfUseAsset	29299	usd
CY2022	TSOI	Increase Decrease In Right Of Use Asset IncreaseDecreaseInRightOfUseAsset	25572	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-1738	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	15166	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-2587	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-9791	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	148288	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	169451	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-29299	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-25572	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1055290	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1037927	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16158	usd
CY2023	TSOI	Payments For Proceeds From Notes Receivable PaymentsForProceedsFromNotesReceivable	7842	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-24000	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	21	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	2453	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	6510	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	285750	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	505000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	4995	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	4459	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	790432	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	445000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1077676	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	943088	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1614	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-94839	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	29437	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	124276	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27823	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	29437	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	2761	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	3173	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1450	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	800	usd
CY2023	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	37500	usd
CY2022	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	39000	usd
CY2023	TSOI	Debt Discount Recorded In Connection With Derivative Liability DebtDiscountRecordedInConnectionWithDerivativeLiability	284565	usd
CY2022	TSOI	Debt Discount Recorded In Connection With Derivative Liability DebtDiscountRecordedInConnectionWithDerivativeLiability	503726	usd
CY2023	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	846217	usd
CY2022	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	1313772	usd
CY2022	TSOI	Common Stock Issued For Prepaid Fees Value CommonStockIssuedForPrepaidFeesValue	242320	usd
CY2023	TSOI	Common Stock Issued For Accrued Salaries Value CommonStockIssuedForAccruedSalariesValue	110000	usd
CY2022	TSOI	Common Stock Issued For Accrued Salaries Value CommonStockIssuedForAccruedSalariesValue	67399	usd
CY2023	TSOI	Accrued Interest Added To Principal AccruedInterestAddedToPrincipal	13126	usd
CY2022	TSOI	Accrued Interest Added To Principal AccruedInterestAddedToPrincipal	25914	usd
CY2022	TSOI	Common Stock Issued For License Value CommonStockIssuedForLicenseValue	3107570	usd
CY2023	TSOI	Common Stock Issued For Land Development CommonStockIssuedForLandDevelopment	96000	usd
CY2022	TSOI	Common Stock Issued For Land Development CommonStockIssuedForLandDevelopment	50400	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	146244	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27823	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18434	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	11003	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27823	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29437	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80A_eus-gaap--NatureOfOperations_zty4VElwpcy3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_822_zJ4ZMswqX815">Organization and Business Description</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therapeutic Solutions International, Inc. (“TSOI” or the “Company”) was organized <span id="xdx_90D_edei--EntityIncorporationDateOfIncorporation_c20230101__20231231_zwBfqEV6m5yc" title="Entity incorporation date">August 6, 2007</span>, under the name Friendly Auto Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business Description</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TSOI is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury, and for daily health.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nutraceutical Division</b> – TSOI has been producing high quality nutraceuticals. Its current flagship product, QuadraMune®, is a multi-patented synergistic blend of pterostilbene, sulforaphane, epigallocatechin-3-gallate, and thymoquinone. QuadraMune has been shown to increase Natural Killer Cell activity and healthy Cytokine production.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regenerative Medicine</b> – TSOI obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability. Subsequent to this acquisition the Company has filed an additional 22 patents on this population of unique mesenchymal like stromal cells.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Immunotherapies</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TSOI has a large portfolio of immunotherapies that range from dendritic cell vaccines for cancers to parkinson’s disease developed on our StemVacs platform.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management does not expect existing cash as of December 31, 2023, to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these financial statements. These financial statements have been prepared on a going concern basis which assumed the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of December 31, 2023, the Company has incurred losses totaling $<span id="xdx_901_eus-gaap--InterestCostsIncurred_pn5n6_c20230101__20231231_zwXsLgDkIjm7" title="Net loss">20.1</span> million since inception, has not yet generated material revenue from operations, and will require additional funds to maintain its operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company’s ability to continue as a going concern is dependent upon its ability to generate future profitable operations and obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating costs over the next twelve months through its existing financial resources and we may also raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. If adequate funds are not available on acceptable terms, we may be required to delay, reduce the scope of, or curtail, our operations. The accompanying consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2007-08-06
CY2023	us-gaap	Interest Costs Incurred InterestCostsIncurred	20100000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6807	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6807	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	98994	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	206767	usd
CY2023	TSOI	Wholesale Purchase Price And Payments Description WholesalePurchasePriceAndPaymentsDescription	Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price. Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail.
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	0	usd
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	0	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	181070	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	202144	usd
CY2021Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	531525	usd
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues	674971	usd
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Net FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet	-713229	usd
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease	-291123	usd
CY2022Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	202144	usd
CY2023	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues	371761	usd
CY2023	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Net FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet	-410671	usd
CY2023	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease	17836	usd
CY2023Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	181070	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_zMSvLqPmITha" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_z5xCkStZOMZ7">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	267136056	shares
CY2022	us-gaap	Depreciation Depreciation	10946	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	233685	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	4132	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	39162	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1452128	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	125557	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	125557	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	301359	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	11037	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	148550	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1167	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1141	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	4116	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	62661	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16320	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	212352	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	413517	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	28281	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	374355	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	273078	usd
CY2023	us-gaap	Depreciation Depreciation	10881	usd
CY2022	us-gaap	Depreciation Depreciation	10946	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	7537	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	4123	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	4123	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2702064	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3002960	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2706187	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3014620	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3261122	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3261122	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	559058	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	258162	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2702064	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3002960	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300897	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	233685	usd
CY2023	us-gaap	Payments Of Derivative Issuance Costs PaymentsOfDerivativeIssuanceCosts	371761	usd
CY2022	us-gaap	Payments Of Derivative Issuance Costs PaymentsOfDerivativeIssuanceCosts	674971	usd
CY2023	us-gaap	Related Party Transaction Rate RelatedPartyTransactionRate	0.005	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.30	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-562532	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-709666	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-123226	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-101347	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	193901	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	405376	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-494107	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-407237	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2250	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1600	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2858356	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2364249	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2858356	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2364249	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	10700000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	9400000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	8700000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	7400000	usd
CY2023	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	net operating loss carryforwards are available to offset taxable income in future years, of which approximately $5 million expires beginning in fiscal 2032
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2023Q4	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	5505000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3802666978	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3802666978	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2	shares
CY2022	TSOI	Stock Issued During Period Values For Salaries StockIssuedDuringPeriodValuesForSalaries	67399	usd
CY2022	TSOI	Stock Issued During Period Value For License StockIssuedDuringPeriodValueForLicense	3107570	usd
CY2022	TSOI	Stock Issued During Period Value For Prepaid Fees StockIssuedDuringPeriodValueForPrepaidFees	242320	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1313772	usd
CY2023	TSOI	Stock Issued During Period Values For Salaries StockIssuedDuringPeriodValuesForSalaries	110000	usd
CY2023	TSOI	Stock Issued During Period Common Stock Issued For Land Development StockIssuedDuringPeriodCommonStockIssuedForLandDevelopment	96000	usd
CY2022Q3	us-gaap	Preferred Stock Voting Rights PreferredStockVotingRights	the Board of Directors designated “Series A Preferred Stock” and caused to be filed a Certificate of Designation pursuant to NRS 78.1955 with the State of Nevada, and upon approval the Board has issued One (1) share of Series A Preferred Stock to Thomas E. Ichim, and One (1) share of Series A Preferred Stock to Timothy G. Dixon. The Holder of the Series A Preferred Stock shall be entitled to vote on all matters subject to a vote or written consent of the holders of the Corporation’s Common Stock, and on all such matters, the share of Series A Preferred Stock shall be entitled to that number of votes equal to the number of votes that all issued and outstanding shares of Common Stock and all other securities of the Corporation are entitled to, as of any such date of determination, on a fully diluted basis, plus One Million (1,000,000) votes, it being the intention that the Holder(s) of the Series A Preferred Stock shall have effective voting control of the Corporation, on a fully diluted basis. The Holder(s) of the Series A Preferred Stock shall vote together with the holders of Common Stock as a single class.
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2	shares
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Area Of Land AreaOfLand	1700	sqft
CY2023Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2028-04-30
CY2023	us-gaap	Payments For Rent PaymentsForRent	25372	usd
CY2022	us-gaap	Payments For Rent PaymentsForRent	25044	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.011	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	27536	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	29248	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	30340	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	31476	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	10620	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	129220	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3663	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	20525	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	105032	usd

Files In Submission

Name	View Source	Status
0001493152-24-014975-index-headers.html	Edgar Link	pending
0001493152-24-014975-index.html	Edgar Link	pending
0001493152-24-014975.txt	Edgar Link	pending
0001493152-24-014975-xbrl.zip	Edgar Link	pending
audit_001.jpg	Edgar Link	pending
audit_002.jpg	Edgar Link	pending
ex3-1.htm	Edgar Link	pending
ex3-11_001.jpg	Edgar Link	pending
ex3-11_002.jpg	Edgar Link	pending
ex3-11_003.jpg	Edgar Link	pending
ex3-11_004.jpg	Edgar Link	pending
ex3-11_005.jpg	Edgar Link	pending
ex3-11_006.jpg	Edgar Link	pending
ex3-1_001.jpg	Edgar Link	pending
ex3-1_002.jpg	Edgar Link	pending
ex3-1_003.jpg	Edgar Link	pending
ex3-1_004.jpg	Edgar Link	pending
ex3-1_1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tsoi-20231231.xsd	Edgar Link	pending
tsoi-20231231_def.xml	Edgar Link	unprocessable
tsoi-20231231_lab.xml	Edgar Link	unprocessable
tsoi-20231231_pre.xml	Edgar Link	unprocessable
tsoi-20231231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TSOI
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Stock $tsoi

2024 Q2 Form 10-K Financial Statement

#000149315224014975 Filed on April 17, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TSOI THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Stock $tsoi

2024 Q2 Form 10-K Financial Statement

#000149315224014975 Filed on April 17, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TSOI
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Stock $tsoi